Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech
Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...
Stocktwits on MSN14h
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves
Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...
pharmaphorum3d
Novo Nordisk agrees $1.1bn takeover of RNA biotech Cardior
Novo Nordisk has reached an agreement to buy Germany’s Cardior Pharmaceuticals for €1.025 billion ($1.1 billion), adding expertise in RNA therapeutics and a heart failure therapy in mid-stage ...